Rchr
J-GLOBAL ID：201401013915626753   Update date: Mar. 01, 2024

Ban Tatsuma

バン タツマ | Ban Tatsuma
Affiliation and department：
Yokohama City University School of Medicine Medical Course

About Yokohama City University School of Medicine Medical Course


Job title： Lecturer
Homepage URL  (1)： http://www-user.yokohama-cu.ac.jp/~immunol/
Research field  (1)： Immunology
Research keywords  (3)： 転写因子 ,  自己免疫疾患 ,  自然免疫応答
Research theme for competitive and other funds  (10)：
  • 2023 - 2026 心筋炎から心筋症への移行を阻止する全く新しい特発性拡張型心筋症の治療法開発に向けた病態解明と治療標的同定
  • 2023 - 2026 新規自己炎症性疾患 VEXAS症候群のdeep phenotypingを通じた病態解明研究
  • 2023 - 2026 転写因子IRF5に注目した全身性エリテマトーデスの新しい病態解明
  • 2020 - 2023 転写因子IRF5阻害剤による全身性エリテマトーデスの革新的治療法とそのコンパニオン診断法の開発
  • 2019 - 2021 自己免疫疾患における形質細胞様樹状細胞の機能疲弊についての解析
Show all
Papers (20)：
  • Feifei Wei, Koichi Azuma, Yoshiro Nakahara, Haruhiro Saito, Norikazu Matsuo, Tomoyuki Tagami, Taku Kouro, Yuka Igarashi, Takaaki Tokito, Terufumi Kato, et al. Machine learning for prediction of immunotherapeutic outcome in non-small-cell lung cancer based on circulating cytokine signatures. Journal for immunotherapy of cancer. 2023. 11. 7
  • Wataru Kawase, Daisuke Kurotaki, Yuta Suzuki, Hiroshi Ishihara, Tatsuma Ban, Go R. Sato, Juri Ichikawa, Hideyuki Yanai, Tadatsugu Taniguchi, Kappei Tsukahara, et al. Irf5 siRNA-loaded biodegradable lipid nanoparticles ameliorate concanavalin A-induced liver injury. Molecular Therapy - Nucleic Acids. 2021. 25. 708-715
  • Tatsuma Ban, Masako Kikuchi, Go R. Sato, Akio Manabe, Noriko Tagata, Kayo Harita, Akira Nishiyama, Kenichi Nishimura, Ryusuke Yoshimi, Yohei Kirino, et al. Genetic and chemical inhibition of IRF5 suppresses pre-existing mouse lupus-like disease. Nature Communications. 2021. 12. 1. 4379-4379
  • Koichi Murakami, Haruka Sasaki, Akira Nishiyama, Daisuke Kurotaki, Wataru Kawase, Tatsuma Ban, Jun Nakabayashi, Satoko Kanzaki, Yoichi Sekita, Hideaki Nakajima, et al. A RUNX-CBFβ-driven enhancer directs the Irf8 dose-dependent lineage choice between DCs and monocytes. Nature Immunology. 2021. 22. 3. 301-311
  • Ryo Saji, Mototsugu Nishii, Kazuya Sakai, Kei Miyakawa, Yutaro Yamaoka, Tatsuma Ban, Takeru Abe, Yutaro Ohyama, Kento Nakajima, Taro Hiromi, et al. Combining IL-6 and SARS-CoV-2 RNAaemia-based risk stratification for fatal outcomes of COVID-19. PloS one. 2021. 16. 8. e0256022
ｍore...
MISC (7)：
ｍore...
Patents (1)：
  • 活性型IRF5を特異的に認識するモノクローナル抗体
Lectures and oral presentations  (14)：
  • 転写因子IRF5の遺伝学的手法および化合物による阻害はマウスSLEモデルにおいて治療効果を示す
    (第17回麒麟塾 2022)
  • Therapeutic effects of genetic and chemical targeting of IRF5 on experimental SLE
    (2021)
  • 全身性エリテマトーデスにおける転写因子IRF5の阻害は現行治療法の限界を克服した新規治療法となる可能性がある
    (第85回日本インターフェロン・サイトカイン学会学術集会 2021)
  • IRF5 as a therapeutic target that overcomes the limitation of current therapies in SLE
    (2019 NIH-Japan-JSPS symposium 2019)
  • IRF5 suppression exerts a therapeutic effect beyond type i interferon blockade on murine SLE
    (7th Annual Meeting of the International Cytokine & Interferon Society 2019)
ｍore...
Education (3)：
  • 2008 - 2012 The University of Tokyo Graduate School of Medicine Pathology, Immunology and Microbiology
  • 2006 - 2008 The University of Tokyo Graduate School of Medicine
  • 2002 - 2006 The University of Tokyo
Professional career (1)：
  • 博士(医学) (東京大学)
Work history (3)：
  • 2022/04 - 現在 Yokohama City University
  • 2013/04 - 2022/03 Yokohama City University
  • 2012/04 - 2013/03 Yokohama City University
Awards (3)：
  • 2019/10 - International Cytokine & Interferon Society Milstein Travel Award
  • 2017/10 - International Cytokine & Interferon Society Milstein Young Investigator Award
  • 2017/05 - Yokohama City University Medical Association Research Award
Association Membership(s) (4)：
International Cytokine & Interferon Society ,  THE MOLECULAR BIOLOGY SOCIETY OF JAPAN ,  THE JAPANESE SOCIETY FOR IMMUNOLOGY ,  日本インターフェロン・サイトカイン学会
※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page

TOP

BOTTOM